Hebei Senlang Biotechnology is focused on the treatment of immune cells new technology development and application of high-tech enterprises.
Hebei Senlang Biotechnology is focused on the treatment of immune cells new technology development and application of high-tech enterprises.The company has the CAR-T research base (Senrang CAR-T Research Center) in North China, and has formed a high-barrier technology platform such as innovative CAR structural design, virus and cell culture , which can take into account technical research and development, hospital clinical application Provide high-quality and effective cellular immunotherapy support for hematological tumors, solid tumors and other tumor diseases, immune system diseases and other patients.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 1, 2018 | Series B | — | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hebei Xianchuang | — | Series B |
Guochuang Investment | — | Series B |